- UCB’s Phase 2a study of bepranemab, an anti-tau antibody for Alzheimer’s, will be presented at CTAD 2024. The study shows promise in delaying disease progression.
- UCB regained global rights from Roche/Genentech.
Tue Oct 22 06:00:50 -0000 2024 UTC– UCB announced results of Phase 2a study on bepranemab, an anti-tau antibody for Alzheimer’s, accepted for CTAD 2024 presentation.
The Clinical Trials on Alzheimer’s Disease conference (CTAD) will be held in Madrid (Spain) on October 29 – November 1, 2024.
The study shows potential to delay disease progression. Symposium on October 31, 2024, will discuss clinical and imaging data. UCB regains global rights to bepranemab.
Blackrock owns close to 5% of UCB, it recently revealed.